Study | Outcome | Number of healthy controls | Reported LMR in healthy controls | Standard deviation | Number of active Crohn’s patients | Reported LMR in active Crohn's | Standard deviation | Number of inactive Crohn’s patients | Reported LMR in inactive Crohn's | Standard deviation | Statistically calculated WMD (95% CI) | Statistically calculated SMD (95% CI) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Marsilio et al. 1998 | Control versus active Crohn’s | 30 | 0.024* | 0.006 | 10 | 0.200* | 0.082 | 0.176 (0.125, 0.227) | 4.373 (3.157, 5.589) | |||
Vilela et al. 2008 | Control versus inactive Crohn’s | 15 | 0.003 | 0.003 | 31 | 0.021 | 0.006 | 0.018 (0.015, 0.021) | 3.467 (2.516, 4.418) | |||
Dastych et al. 2008 | Control versus active Crohn’s | 20 | 0.012* | 0.008 | 20 | 0.076* | 0.037 | 0.064 (0.047, 0.081) | 2.396 (1.575, 3.217) | |||
D'Inca et al. 2006 | Control versus inactive Crohn’s versus first degree relatives | 35 | 0.01 | 0.003 | 115 | 0.03 | 0.045 | 0.020 (0.012, 0.028) | 0.506 (0.123, 0.889) | |||
Wild et al. 2003 | Control versus inactive Crohn’s patients after 10 weeks of tapering steroids who eventually relapsed | 23 | 0.021* | 0.004 | 11 | 0.055* | 0.018 | 0.05 (0.04, 0.07) | 3.209 (2.144, 4.274) | |||
Wild et al. 2003 | Control versus inactive Crohn’s patients after 10 weeks of tapering steroids who eventually did not relapse | 23 | 0.021* | 0.004 | 11 | 0.026* | 0.017 | 0.497 (-0.232, 1.225) | ||||
Wild et al. 2003 | Control versus active Crohn’s patients | 23 | 0.021* | 0.004 | 30 | 0.088* | 0.026 | 0.067 (0.058, 0.076) | 3.387 (2.534, 4.240) | |||
Wild et al. 2003 | Active Crohn’s patients versus inactive Crohn’s patients after 10 weeks of tapering steroids who eventually relapsed | 30 | 0.088* | 0.026 | 11 | 0.055* | 0.018 | 0.033 (0.019, 0.047) | 1.364 (0.609, 2.118) | |||
Wild et al. 2003 | Active Crohn’s patients versus inactive Crohn’s patients after 10 weeks of tapering steroids who eventually did not relapse | 30 | 0.088* | 0.026 | 11 | 0.026* | 0.017 | 0.062 (0.048, 0.076) | 2.582 (1.684, 3.479) | |||
Garcia Vilela et al. 2008 | Control versus inactive Crohn’s | 15 | 0.005* | 0.004 | 31 | 0.021* | 0.010 | 0.016 (0.012, 0.020) | 1.879 (1.148, 2.609) | |||
Sigalet et al. 2013 | Control versus active Crohn’s | 10 | 0.029* | 0.008 | 7 | 0.056* | 0.025 | 0.026 (0.007, 0.045) | 1.531 (0.421, 2.641) | |||
Sigalet et al. 2013 | Control versus inactive Crohn’s | 10 | 0.029* | 0.008 | 7 | 0.032* | 0.010 | 0.002 (-0.007, 0.011) | 0.226 (-0.743, 1.195) | |||
Sigalet et al. 2013 | Active versus inactive Crohn’s | 7 | 0.056* | 0.025 | 7 | 0.032* | 0.010 | 0.024 (0.004, 0.044) | 1.261 (0.098, 2.423) | |||
Zamora et al. 1999 | Control versus inactive Crohn’s | 21 | 0.019 | 0.01 | 14 | 0.027 | 0.040 | 0.008 (-0.013,0.030) | 0.313 (-0.368, 0.993) | |||
Andre et al. 1988 | Control versus active Crohn’s | 100 | 0.021* | 0.01 | 15 | 0.132* | 0.11 | 0.111 (0.055, 0.167) | 2.787 (2.134, 3.440) | |||
Andre et al. 1988 | Control versus inactive Crohn’s | 100 | 0.021* | 0.01 | 15 | 0.074* | 0.090 | 0.053 (0.007,0.099) | 1.604 (1.023, 2.186) | |||
Andre et al. 1988 | Active versus inactive Crohn’s | 15 | 0.132* | 0.11 | 15 | 0.074* | 0.090 | 0.058 (-0.014, 0.130) | 0.577 (-0.154, 1.309) | |||
Sturniolo et al. 2001 | Inactive Crohn’s | 12 | 0.041* | 0.010 | ||||||||
Buhner et al. 2006 | Control versus inactive Crohn’s versus first degree relatives versus non-blood relatives | 96 | 0.015 | 0.005 | 128 | 0.026 | 0.016 | 0.011 (0.008, 0.014) | 0.877 (0.601, 1.154) | |||
D'Inca et al. 1999 | Control versus Inactive Crohn’s patients who eventually relapsed | 80 | 0.009* | 0.004 | 52 | 0.045* | 0.042 | 0.036 (0.025, 0.047) | 1.359 (0.973, 1.745) | |||
D'Inca et al. 1999 | Control versus Inactive Crohn’s patients who eventually did not relapse | 80 | 0.009* | 0.004 | 78 | 0.027* | 0.027 | 0.018 (0.012, 0.024) | 0.938 (0.610, 1.267) | |||
Swanson et al. 2011 | Control versus inactive Crohn’s | 7 | 0.094** | 6 | 0.085** | |||||||
Benjamin et al. 2012a | Inactive Crohn’s | 15 | 0.067 | 0.024 | ||||||||
Benjamin et al. 2012b | Inactive Crohn’s | 15 | 0.071 | 0.061 | ||||||||
Hilsden et al. 1996 | Controls versus first degree relatives of Crohn’s patients in remission | 26 | 0.017* | 0.006 | ||||||||
Hilsden et al. 1999 | Inactive Crohn’s | 61 | 0.018* | 0.011 | ||||||||
Breslin et al. 2001 | Controls versus spouses of patients with inactive Crohn’s | 26 | 0.017* | 0.005 |